Literature DB >> 9777887

Molecular genetics of human leukemia.

D G Gilliland1.   

Abstract

Human leukemias are clonal hemopathies generally characterized by acquired somatic mutations, including translocations, deletions, and insertions. Ten years ago, the first leukemia-related chromosomal translocation, the Philadelphia chromosome, was cloned and fully characterized at the molecular level. Since then, a plethora of chromosomal translocations and mutations has been associated with leukemogenesis. Analysis and comparison of this bewildering array of genetic changes have helped identify shared paradigms and themes in the mechanisms of transformation of hematopoietic cells. This information will guide the development of improved therapies that take into account the cytogenetic and molecular characteristics of human leukemias. This review summarizes the current knowledge of the nature of the genetic changes associated with leukemogenesis and discusses their consequences at the molecular and cellular levels.

Entities:  

Mesh:

Year:  1998        PMID: 9777887

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages.

Authors:  Shireen Saleque; Scott Cameron; Stuart H Orkin
Journal:  Genes Dev       Date:  2002-02-01       Impact factor: 11.361

2.  PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.

Authors:  Yutaka Shima; Takito Shima; Tomoki Chiba; Tatsuro Irimura; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

3.  Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase, dietary folate intake, and the risk of leukemia in adults.

Authors:  Ping Liu; Min Zhang; Xing Xie; Jie Jin; C D'Arcy J Holman
Journal:  Tumour Biol       Date:  2015-10-05

4.  Immunologic consequences of chemotherapy for acute myeloid leukemia.

Authors:  Anne Reilly; Leslie S Kersun; Eline Luning Prak; Jean Boyer; Kenyetta McDonald; Abbas F Jawad; Kathleen E Sullivan
Journal:  J Pediatr Hematol Oncol       Date:  2013-01       Impact factor: 1.289

5.  Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene.

Authors:  C L Dobson; A J Warren; R Pannell; A Forster; T H Rabbitts
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

6.  Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.

Authors:  Kuan-Po Huang; Andrew J Chase; Nicholas C P Cross; Andrea Reiter; Tzu-Ying Li; Tso-Fu Wang; Sung-Chao Chu; Xuan-Yin Lu; Chi-Cheng Li; Ruey-Ho Kao
Journal:  Int J Hematol       Date:  2008-07-02       Impact factor: 2.490

Review 7.  New molecular methods for classification, diagnosis and therapy prediction of hematological malignancies.

Authors:  Agnes Zvara; László Hackler; Zsolt B Nagy; Tamás Micsik; László G Puskás
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 2.874

8.  Esculetin Downregulates the Expression of AML1-ETO and C-Kit in Kasumi-1 Cell Line by Decreasing Half-Life of mRNA.

Authors:  Sharad Sawney; Rashi Arora; Kamal K Aggarwal; Daman Saluja
Journal:  J Oncol       Date:  2015-03-11       Impact factor: 4.375

9.  Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia.

Authors:  Fei-Fei Wang; Ming-Zhu Liu; Yi Sui; Qing Cao; Bo Yan; Mei-Ling Jin; Xi Mo
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

10.  First report from a single center retrospective study in Kazakhstan on acute myeloid leukemia treatment outcomes.

Authors:  G U Kulkayeva; V M Kemaykin; A M Kuttymuratov; Z I Burlaka; J Z Saparbay; G T Zhakhina; A A Adusheva; S D Dosayeva
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.